v3.26.1
Organization , Description of Business and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Third-party Payers as a Percentage of Total
The Company’s total third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:
 
 Three Months Ended March 31,
 20262025
Medicare34 %33 %
UnitedHealthcare13 %13 %
 47 %46 %
The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:
 
 March 31, 2026December 31, 2025
Medicare23 %20 %
UnitedHealthcare16 %14 %
Schedule of Revenue Revenue included in biopharmaceutical and other revenue for the three months ended March 31, 2026 and 2025 was as follows (in thousands of dollars):
 Three Months Ended March 31,
 20262025
Biopharmaceutical revenue$301 $2,297 
Contract manufacturing and testing— 1,287 
Total$301 $3,584